A respected RNAi therapeutics firm.

The primary theme of the meeting is normally ‘Chemistry for Combating and Preventing Disease,’ and the presentations are being produced at the Oligonucleotide Therapeutics Symposium structured by the Carbohydrate Division of ACS. Data being presented by Alnylam scientists at this meeting include new results on style, synthesis, and characterization of siRNAs, siRNA conjugates, and delivery formulations. Certainly, these cumulative data demonstrate Alnylam’s continuing scientific leadership in the advancement of RNAi therapeutics as a new class of innovative medications,’ stated Muthiah Manoharan, Ph.D., Senior Vice President, Drug Discovery.Fragile X is the most common known reason behind autism or ‘autistic-like’ behaviors. The disease is caused by a mutation in the FMR gene on the X chromosome and effects approximately one in 3,600 males and one in 4,000 to 6,000 females. The TRND program is made to encourage the development of medicines for neglected and rare diseases. The program aims to swiftness development of new medications that might normally be ignored by industry because they are too early in the development process where the failure rates are high.